ATIP-Avenir Team Chassin, University Paris Diderot, Sorbonne Paris Cité, CRI, UMR 1149, Inserm, Paris, France.
J Innate Immun. 2018;10(1):14-29. doi: 10.1159/000480248. Epub 2017 Oct 26.
Urinary tract infections (UTIs) mainly due to uropathogenic Escherichia coli (UPEC) are one of the most frequent complications in kidney-transplanted patients, causing significant morbidity. However, the mechanisms underlying UTI in renal grafts remain poorly understood. Here, we analysed the effects of the potent immunosuppressive agent cyclosporine A (CsA) on the activation of collecting duct cells that represent a preferential site of adhesion and translocation for UPEC. CsA induced the inhibition of lipopolysaccharide- induced activation of collecting duct cells due to the downregulation of the expression of TLR4 via the microRNA Let-7i. Using an experimental model of ascending UTI, we showed that the pretreatment of mice with CsA prior to infection induced a marked fall in cytokine production by collecting duct cells, neutrophil recruitment, and a dramatic rise of bacterial load, but not in infected TLR4-defective mice kidneys. This effect was also observed in CsA-treated infected kidneys, where the expression of Let-7i was increased. Treatment with a synthetic Let-7i mimic reproduced the effects of CsA. Conversely, pretreatment with an anti-Let-7i antagonised the effects of CsA and rescued the innate immune response of collecting duct cells against UPEC. Thus, the utilisation of an anti-Let-7i during kidney transplantation may protect CsA-treated patients from ascending bacterial infection.
尿路感染(UTIs)主要由尿路致病性大肠杆菌(UPEC)引起,是肾移植患者最常见的并发症之一,可导致严重的发病率。然而,肾移植中尿路感染的机制仍知之甚少。在这里,我们分析了强效免疫抑制剂环孢素 A(CsA)对代表 UPEC 优先粘附和易位部位的集合管细胞激活的影响。由于 microRNA Let-7i 的下调导致 TLR4 表达的下调,CsA 诱导了脂多糖诱导的集合管细胞激活的抑制。使用上行性尿路感染的实验模型,我们表明,在感染前用 CsA 预处理小鼠可显著降低集合管细胞的细胞因子产生、中性粒细胞募集和细菌负荷的急剧增加,但在感染 TLR4 缺陷型小鼠的肾脏中则不会。在 CsA 处理的感染肾脏中也观察到了这种效应,其中 Let-7i 的表达增加。用合成的 Let-7i 模拟物进行治疗可再现 CsA 的作用。相反,用抗 Let-7i 进行预处理可拮抗 CsA 的作用,并挽救集合管细胞对 UPEC 的固有免疫反应。因此,在肾移植期间使用抗 Let-7i 可能会保护 CsA 治疗的患者免受上行性细菌感染。